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Abstract 1 
Background: Cancerous and non-cancerous respiratory diseases are common and contribute 2 
significantly to global disease burden. We aim to quantify the association between plasma 3 
vitamin C concentrations as an indicator of high fruit and vegetable consumption and the risk 4 
of incident respiratory diseases and associated mortality in a general population. 5 
Methods: 19,357 men and women aged 40-79 years without prevalent respiratory diseases at 6 
the baseline (1993-1997) and participating in the European Prospective Investigation into 7 
Cancer (EPIC)-Norfolk study in the UK were followed through March 2015 for both 8 
incidence and mortality from respiratory diseases. 9 
Results: There were a total of 3914 incident events and 407 deaths due to any respiratory 10 
diseases (excluding lung cancers), 367 incident lung cancers and 280 lung cancer deaths 11 
during the follow up (total person years >300,000 years). Cox proportional hazards models 12 
showed, persons in the top quartiles of baseline plasma vitamin C concentrations had a 43% 13 
lower risk of lung cancer (HR 0.57; 95%CI:0.41-0.81) than did those in the bottom quartile, 14 
independently of potential confounders. The results are similar for non-cancerous any 15 
respiratory disease (HR 0.85;0.77-0.95), chronic respiratory diseases (HR0.81;0.69-0.96), and 16 
pneumonia (HR0.70;0.59-0.83). The corresponding values for mortality were 0.54(0.35- 17 
0.81), 0.81(0.59-1.12), 0.85(0.44-1.66), and 0.61(0.37-1.01), respectively. Confining 18 
analyses to non-smokers showed 42% and 53% risk reduction of non-smoking related lung 19 
cancers incidence and death. 20 
Conclusions: Higher levels of vitamin C concentrations as a marker of high fruit and 21 
vegetable consumption reduces the risk of cancerous and non-cancerous respiratory illnesses 22 
including non-smoking related cancers incidence and deaths. 23 
   24 
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Introduction 34 
 35 
Respiratory diseases are major causes of mortality and morbidity worldwide. In the UK 36 
alone, respiratory disease costs the NHS and society £6.6 billion: £3 billion in costs to the 37 
care system, £1.9 billion in mortality costs and £1.7 billion in illness costs [1]. Irreversible 38 
progressive chronic respiratory diseases and pneumonia are common in middle and older age 39 
and contribute significantly to this burden. Whilst lung cancer incidence is declining in some 40 
countries which imposed smoking ban, there remains risk of lung cancers in general as well 41 
as the risk of non-smoking related lung cancer.  42 
 43 
Whilst the intake of high fruit and vegetables depicted by plasma vitamin C concentrations 44 
are linked to mortality [2] and chronic cardiovascular conditions including stroke [3-7]. 45 
Whether such dietary health behaviour is linked to respiratory diseases including pneumonia 46 
is less well understood. Plasma vitamin C levels can be regarded as a reasonably reliable 47 
measure of not just the intake of fruit and vegetables, but the in vivo biologically available 48 
vitamin C for human physiological functions because it cannot be synthesized in the body. It 49 
is because the main source of vitamin C is from dietary fruit, vegetables, and plant foods in 50 
humans but is easily denatured by food preparation methods (e.g. via cooking in water, 51 
roasting, or grilling) [8]. It also has a short half-life (≈30 min) in the blood [9,10]. Therefore, 52 
random plasma vitamin C level is most likely to reflect an individual's habitual dietary 53 
pattern as well as  method of food preparation.  54 
 55 
The relationship between plasma vitamin C concentrations and the incidence of chronic 56 
obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia and respiratory 57 
mortality including lung cancer deaths, in particular non-smoking related lung cancers and 58 
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their associated mortality risks were poor understood.  We explored these relationships in the 59 
European Prospective Investigation into Cancer (EPIC)–Norfolk. Our secondary objective 60 
was to examine whether the relationship, if existed, vary by age, sex, smoking status, 61 
physical activity level, and lung function assessed by forced expiratory volume in the first 62 
second (FEV1). We then further assessed the relationship between higher level of fruit and 63 
vegetable consumption and non-smoking related incidence and mortality for these conditions.  64 
 65 
  66 
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Subjects and Methods 67 
 68 
Participants 69 
Participants were drawn from the EPIC-Norfolk prospective population study. The detailed 70 
recruitment method and study protocol of EPIC-Norfolk were described previously [11]. 71 
Briefly, all eligible community-dwelling adults (aged 40-79 years at the baseline (1993-72 
1997)) from 35 participating general practices in Norfolk, UK, were invited to participate. A 73 
total of 30,445 (~40% response) persons provided written consent to participate in the study 74 
(99.6% British Caucasians). The Norwich Local Research Ethics Committee approved the 75 
study.  76 
 77 
Measurements 78 
At the time of the baseline survey, participants completed a detailed health and lifestyle 79 
questionnaire and attended health check clinic where trained nurses performed clinical 80 
assessments.  The data collection methods for variables included in this study are described 81 
details in the online supplement [12-17].  82 
 83 
Assessment of Vitamin C levels 84 
After overnight storage in a dark box at 4–7 °C, non-fasting blood samples were centrifuged 85 
at 2100×g for 15 min at 4 °C. Plasma vitamin C was measured from blood collected one year 86 
later when funding was available  using fluorometric assay within 1 week of sampling [18]. 87 
The mean coefficients of variation (CV) were  33.2 μmol/L at the lower end and 102.3 88 
μmol/L at the upper end.  89 
 90 
Outcome ascertainment 91 
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Incident cases were ascertained by using death certificate data and hospital record linkage 92 
based on UK Office of National Statistics using International Classification of Disease (ICD), 93 
revisions 9 and 10 and National Health Service hospital information systems through 94 
ENCORE ((ENCORE – East Norfolk COmmission REcord). Accuracy of this method has 95 
been previously validated [19]. Hospitalisation record was linked up to end of March 2015 96 
and death was monitored until end March 2015. Conditions of interest are any respiratory 97 
conditions (ICD codes 460-519; J00-J99, chronic respiratory conditions ICD codes 490-496; 98 
J40-47,pneumonia, ICD 10 J12-J18, B012,B052,B953,B960,B961,J100, J110,J851, Lung 99 
cancers (C33-C34) and asthma (J45-J46).  Whilst incident and morality from asthma was 100 
included in all non-cancerous respiratory diseases, it was specifically excluded from 101 
outcomes as adult/older age onset asthma may have other mechanistic pathways which are 102 
non-dietary. 103 
 104 
 105 
 106 
Statistical analysis 107 
Statistical analysis was performed using Stata Version 14.1/SE (StatCorLP, USA. Texas, 108 
USA).  All tests are two-sided and, as the study is exploratory, no adjustment for multiple 109 
comparisons has been made. Any participants with missing value for any of the variables 110 
included in the analyses were excluded in individual analyses. Plasma vitamin C 111 
concentration was split into quartiles, with cut-points 41, 54, and 66 μmol/L. The percentage 112 
of predicted normal were calculated for FVC and FEV1 (FVC% predicted and FEV1% 113 
predicted respectively) based on the Steel and Coal formula [20]. The incidence of respiratory 114 
conditions and respiratory related mortality are reported descriptive, firstly overall and then 115 
stratified by the quartiles of plasma vitamin C concentrations. 116 
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 117 
Cox proportional hazards models were constructed to determine  the association between 118 
plasma vitamin C concentrations and the subsequent risk of all respiratory conditions, chronic 119 
respiratory disease, and pneumonia. The risks of mortality for each of the selected outcomes 120 
were also assessed. To estimate the independent contribution of vitamin C concentration we 121 
controlled for 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and 122 
FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking, alcohol consumption, 123 
physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational 124 
social class and Townsend index of deprivation; 5) as in model 3 with additional adjustment 125 
for prevalent diabetes, myocardial  infarction (MI) and stroke; 6) as in model 4 with 126 
additional adjustment for history of diabetes, MI and stroke; and finally model 7 was 127 
constructed as in model 6 after excluding participants who were taking vitamin C containing 128 
supplements.  129 
 130 
To assess the differences in the relationship between plasma concentration of vitamin C at the 131 
baseline and the subsequent incidence of respiratory diseases including mortality specifically 132 
in different age groups (younger and older (<65 years and >=65 years)), sex (men and 133 
women), smoking status (current smokers and non/ex-smokers), physical activity levels 134 
(inactive and active), and respiratory function (good and poor function; people with good 135 
function defined as people in the top quartile of FEV1 values) the stratified analyses were 136 
repeated for model 6. 137 
 138 
Analyses were then repeated for main analyses for final two models (models 6 and 7) 139 
confining first to non-current smokers and then to never-smokers.  140 
 141 
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Results 143 
 144 
A total of 25,639 individuals attended their first health check in EPIC-Norfolk during 1993-145 
1997, of these 1,410 were excluded as they had an existing diagnosis of cancer leaving 146 
24,229 individuals. Of these, 2205 had self-reported respiratory diseases and/or taking 147 
bronchodilators or drugs for asthma or COPD at the baseline; this leaves 22,024 individuals. 148 
After exclusion of 2,685 individuals who did not have vitamin C measurements and further 3 149 
participants with missing follow-up data we included a total of 19,336 men and women in the 150 
current study.  The mean follow-up was 16.54 years. The total follow-up period for the 151 
incidence was 319,937 person-years and for the mortality outcome was 336,473 person-years.  152 
There were a total of 3,914 incident cases and 407 deaths during the respective follow up 153 
periods. 154 
 155 
Table 1 shows the sample characteristics by quartiles of plasma vitamin C concentrations. 156 
The quartile values were =< 41 μmol/L, 42-54 μmol/L, >54-=<66.0 μmol/L, and >66.0  157 
μmol/L for quartiles 1,2, 3 and 4, respectively. This shows significant trends for all selected 158 
variables across the plasma vitamin C categories.  People with the higher levels of plasma 159 
vitamin C levels were younger, had better baseline lung functions, materially less likely to be 160 
deprived, lower proportion of men, less likely to be current smokers and consumed less 161 
amount of alcohol, had higher level of education and occupational social class, physically 162 
more active, and had lower prevalence of chronic co-morbid conditions.  The crude rates for 163 
all the selected outcomes suggest a direct relationship between higher baseline plasma 164 
vitamin C concentrations and a better outcome (lower event rates).  165 
 166 
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Table 2 shows the hazards ratios and their corresponding 95% confidence intervals for 167 
development of incident any respiratory diseases including chronic respiratory diseases (e.g. 168 
COPD/pulmonary fibrosis etc.) and pneumonia over the follow up period. Compared to the 169 
people in the bottom quartiles, the people in the highest levels of baseline plasma ascorbic 170 
concentrations had significant 15%, 19% 30% and 47% relative risk reduction of having any 171 
respiratory conditions, chronic respiratory diseases, hospitalised pneumonia, and lung cancer 172 
respectively in adjusted model (model 6). The corresponding relative risk reduction for 173 
mortality from these conditions were 13%, 37% and 34% and 52%, respectively, although 174 
these did not reach to statistical significance (Table 3) with the exception of lung cancer, 175 
which showed relative risk reduction of 46%. Excluding those participants who took vitamin 176 
C containing supplements did not alter the association (model 7, Tables 2 &3).  177 
 178 
Figure 1 (a-d) show the stratified analyses by age groups (younger and older (<65 years and 179 
>=65 years)), sex (men and women), smoking status (current smokers, non/ex-smokers), 180 
physical activity (active, inactive), and respiratory function (good function defined as top 181 
quartile of FEV1 value, and poor function defined as the lower three quartiles) for all 182 
outcomes examined for those in top quartile of vitamin C concentrations compared to the 183 
bottom quartile.   The benefit of high levels of fruit and vegetable consumption depicted by 184 
random plasma vitamin C concentrations was associated with younger age but generally all 185 
subgroups showed consistent trends towards benefit with regard to all outcomes examined.  186 
People with lower FEV1 also appear to be benefited from higher fruit and vegetable 187 
consumption compared to people with better FEV1.  With reduced statistical power most of 188 
the sub-analyses shown in Supplementary Table 1 for mortality outcome, whilst most of the 189 
estimates did not show any significant benefit with regard to mortality due to these conditions 190 
13 
 
but the point estimates are in consistent with potential benefit across age group, sex, smoking 191 
status, physical activity, and the level of FEV1. 192 
Supplementary Table 2 shows the results confining to non-smokers and never-smokers for 193 
both incidence and mortality of all these respiratory diseases. With lower numbers whilst the 194 
95%CI are wider, the point estimates show similar direction. Of note, the non-smoking 195 
related lung cancer incidence and mortality showed stronger benefit 42% and 53% relative 196 
risk reduction in non-current smokers in people with top quartiles of vitamin C 197 
concentrations compared to the bottom quartile. Supplementary Figure 1 shows the Kaplan-198 
Meier estimates of survival based on different events. The graphs are top-left for all 199 
respiratory events, top right for lung cancer events, bottom-left for chronic respiratory disease 200 
event, and bottom right for pneumonia events. 201 
 202 
  203 
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Discussion 204 
 205 
Plasma vitamin C concentration is a good biomarker of plant food, namely fruit and 206 
vegetables intake. We found for the first time that the higher habitual intake of fruit and 207 
vegetables depicted by higher plasma vitamin C concentrations at the baseline predict future 208 
incidence of any respiratory diseases (excluding cancer), chronic respiratory diseases and 209 
hospitalised pneumonia in a general population. Further we demonstrate significant relative 210 
risk reduction in lung cancer incidence as well as lung cancer related mortality by higher 211 
level of baseline plasma vitamin C concentrations. The observed effects are even more 212 
pronounced for non-current smokers. The benefit observed with each higher quartiles of 213 
plasma vitamin C is fairly consistent and the most beneficial relative risk reduction was 214 
observed in the top quartile and the cut off point for the highest quartile in this study was >66 215 
μmol/L. Given that one serving of fruit and vegetables in our cohort equates to 20-μmol or 1-216 
SD increase in plasma vitamin C concentration [2], it can be extrapolated from our results 217 
that at the level of 3.5 portions of fruit and vegetable consumption could lead to significant 218 
health benefit within a general population.   219 
 220 
It is well recognised that fresh rather than cooked or boiled fruit and vegetables are a richer 221 
source of vitamin C. Due to their antioxidant property, higher levels of vitamin C are thought 222 
to be associated with reduced inflammatory process/insult.  However, there appears to be 223 
distinct lack of nutritional interventions in respiratory diseases except vitamin 224 
supplementation with only a few short term studies evaluating supplementation with 225 
vitamins. The link between vitamin C intake and lung cancer incidence has been previously 226 
investigated [21]. We have furthered this knowledge and shown that high consumption of 227 
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fruit and vegetables also potentially have substantial survival benefit with relative risk 228 
reduction of 46%. 229 
 230 
One short term study of Vitamin C and E showed no change in lung function in 24 COPD 231 
patients [22]. In a larger 5-year trial of more than 20,000 patients with coronary disease, other 232 
occlusive arterial disease, or diabetes, there was no difference in lung function or COPD 233 
related outcomes [23].   A Cochrane review of vitamin C treatment for pneumonia identified 234 
3 prophylactic studies conducted more than 30 years ago involving 2335 people from which 235 
37 developed community-acquired pneumonia. In all of these studies there was a significant 236 
reduction in the development of pneumonia however only one study (of 674 marine recruits) 237 
was a randomised trial and the evidence was felt to be too weak to advocate prophylactic use 238 
of vitamin C to prevent pneumonia in the general population [24].  239 
 240 
Data from the Third National Health and Nutrition Examination Survey, a US population-241 
based cross-sectional study suggest that serum vitamin C concentration is independently 242 
related to lung function as assessed by FEV1 [25] whereas serum vitamin C concentration is 243 
associated with FVC in patients with airflow obstruction [26].  Other authors have shown the 244 
concentration of vitamin C to be inversely related to all-cause mortality in adults with 245 
obstructive lung disease [27] and mean intake of vitamin C is significantly lower in patients 246 
with COPD than controls [28].  247 
 248 
Reactive oxygen species are produced by inflammatory cells including neutrophils and 249 
macrophages or are inhaled as environmental agents or cigarette smoke. Oxidants result in 250 
cellular damage and may result in apoptosis or cellular necrosis, induce mucous secretion or 251 
alter remodelling of extracellular matrix [29] all of which may contribute to the 252 
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pathophysiology of obstructive lung diseases. Indeed, vitamin C has recently be shown to 253 
prevent smoke-induced emphysema in mice that cannot synthesise vitamin C suggesting that 254 
vitamin C reduced the oxidative stress caused by cigarette smoking [30] and therefore are not 255 
simply a reflection of diet. Interestingly, in the current study, people in the lowest quartile of 256 
vitamin C had the highest proportion of those with smoking history – Vitamin C has been 257 
shown to be required to have an adequate immune response to influenza virus infection in 258 
mice [31] and micronutrient deficiencies (including vitamin C) are associated with impaired 259 
immune response and higher burden of respiratory infections in elderly humans [32].   260 
 261 
There are some limitations which worth discussing. The initial response rate was modest 262 
(~40%).  Nevertheless, the baseline characteristics of the study population were similar to 263 
those of other UK population samples, with the exception of slightly lower prevalence of 264 
smokers [11] which may be related to healthy responder bias. Whilst the lower prevalence of 265 
smoking may have some impact on vitamin C levels, the internal relationships between 266 
vitamin C levels and incidence respiratory diseases are unlikely to be affected by this. 267 
Moreover, the truncation of distribution is more likely to attenuate the associations. . 268 
Although follow-up is virtually complete, using hospital record and death certificate linkage 269 
approach may underestimate events that are not admitted to the hospital e.g. milder forms of 270 
pneumonia.   271 
 272 
The use of self-reported respiratory conditions may have missed some prevalent respiratory 273 
conditions. Plasma vitamin C and other covariates, were made at baseline. These measures as 274 
well as lifestyle behaviours, which may affect vitamin C concentration, may have changed 275 
over the follow-up period. Due to missing data in some of the variables included in the 276 
models, the number of participants included in the analysis reduced with higher level of 277 
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adjustments but the findings were consistent and adjustments did not particularly attenuate 278 
the results.  279 
 280 
We addressed confounding and reverse causality issues by comprehensive adjustment of 281 
possible confounders.  We also performed sensitivity analysis for supplements usage. The 282 
incident cases were identified after 1998, at least one year after the baseline. Prospective 283 
relationship between baseline vitamin C concentrations and incidence and mortality also 284 
suggests potential causal link, or at least the marker of the conditions examined in this study. 285 
We performed sensitivity analyses by confining analyses to those who were non-current 286 
smokers and never-smokers.  287 
 288 
To conclude, we found that high plasma vitamin C concentrations at baseline are significantly 289 
associated with the lower incidence of lung cancer, any respiratory illness other than lung 290 
cancer, chronic respiratory diseases and pneumonia. Additionally, those in highest 291 
consumption of fruit and vegetables (Quartile 4 of plasma vitamin C concentrations) also had 292 
46% relative risk reduction from lung cancer mortality (53% in those who were non-current 293 
smokers at the baseline) compared to the bottom quartile. Therefore, the plasma vitamin C 294 
level may be useful in identification of those at risk of these both cancerous and non-295 
cancerous respiratory diseases at the population level. As vitamin C level in plasma is 296 
associated with higher fruit and vegetable consumption, increased consumption of fruit and 297 
vegetables may reduce the risk of these respiratory conditions and associated health care cost 298 
globally.  299 
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Figure Legends 300 
Figure 1: Hazard ratios for study outcomes in people in the highest quartile group (Q4) 301 
compared to the lowest quartile group (Q1) stratified by important factors for model 6. 302 
Figure 1 (a): Incident respiratory illness  303 
Figure 1 (b): Incident lung cancer  304 
Figure 1 (c): Incident chronic respiratory diseases  305 
Figure 1 (d): Incident pneumonia  306 
  307 
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Table 1: Baseline characteristics of men and women of EPIC-Norfolk 39-79 years old at the baseline by plasma vitamin C quartile categories  441 
 Vitamin C quartiles      
Characteristics Q1 (3-41 umol/l) 
N = 5068 
Q2 (42-54 umol/l) 
N = 4849 
Q3 (54.1-66 umol/l) 
N = 4868 
Q4 (66-242 umol/l) 
N = 4554 
p-for trend 
      
Vit C in plasma (umol/l) 28.19 (9.69) 48.51 (3.71) 60.26 (3.38) 78.77 (13.01) <0.001 
Age (years) 60.07 (9.40) 58.93 (9.39) 58.28 (9.03) 58.53 (9.16) <0.001 
FVC (% pred) 87.99 (18.64) 91.43 (18.64) 94.57 (18.36) 96.32 (18.99) <0.001 
FEV1 (% pred) 88.90 (17.94) 92.42 (17.19) 94.81 (16.62) 95.78 (17.29) <0.001 
Townsend index -1.82 (2.33) -2.14 (2.07) -2.19 (2.08) -2.16 (2.08) <0.001 
Male 3294 (65.0%) 2629 (54.2%) 1924 (39.5%) 1190 (26.1%) <0.001 
Current smoker 1048 (20.8%) 464 (9.6%) 389 (8.1%) 344 (7.6%) <0.001 
Alcohol consumption (grams/week) 8.98 (14.56) 9.01 (13.28) 8.41 (12.02) 8.41 (11.75) 0.023 
BMI > 30 kg/m2 934 (18.5%) 814 (16.8%) 617 (12.7%) 403 (8.9%) <0.001 
Educational attainment 
   
 <0.001 
            None 2155 (42.5%) 1761 (36.4%) 1627 (33.4%) 1522 (33.4%)  
            O-level 472 (9.3%) 498 (10.3%) 494 (10.2%) 525 (11.5%)  
            A-Level 1988 (39.2%) 1974 (40.8%) 2016 (41.4%) 1813 (39.8%)  
            Degree or higher 452 (8.9%) 611 (12.6%) 728 (15.0%) 693 (15.2%)  
Occupational social class 
   
 <0.001 
24 
 
            Professional  270 (5.5%) 312 (6.6%) 365 (7.6%) 361 (8.1%)  
            Managerial  1508 (30.6%) 1694 (35.7%) 1856 (38.8%) 1859 (41.6%)  
            Skilled non-manual  723 (14.7%) 797 (16.8%) 837 (17.5%) 739 (16.5%)  
            Skilled manual 1403 (28.5%) 1155 (24.4%) 993 (20.7%) 881 (19.7%)  
            Semi-skilled  790 (16.0%) 636 (13.4%) 585 (12.2%) 527 (11.8%)  
            Non-skilled  235 (4.8%) 149 (3.1%) 152 (3.2%) 102 (2.3%)  
Physically inactive 
3139 (61.9%) 2859 (59.0%) 2749 (56.5%) 2501 (54.9%) 
<0.001 
 
 Myocardial infarction (yes) 
249 (4.9%) 151 (3.1%) 114 (2.3%) 81 (1.8%) 
<0.001 
 
Diabetes (yes) 
169 (3.3%) 127 (2.6%) 78 (1.6%) 43 (0.9%) 
<0.001 
 
Stroke (yes) 
100 (2.0%) 57 (1.2%) 52 (1.1%) 45 (1.0%) 
<0.001 
 
 
Outcomes 
     
 
Hospitalisations      
    
            All (ex-lung cancer) 1237 (24.4%) 977 (20.1%) 865 (17.8%) 727 (16.0%) 
<0.001 
 
            Lung cancer 162 (3.2%) 64 (1.3%) 49 (1.0%) 50 (1.1%) <0.001 
            Chronic respiratory illnesses 503 (9.9%) 352 (7.3%) 307 (6.3%) 268 (5.9%) <0.001 
25 
 
 
           Pneumonia 
463 (9.1%) 337 (6.9%) 285 (5.9%) 214 (4.7%) 
<0.001 
 
Mortality       
            All (ex-lung cancer) 
147 (2.9%) 104 (2.1%) 86 (1.8%) 70 (1.5%) 
<0.001 
 
            Lung cancer 143 (2.8%) 56 (1.2%) 45 (0.9%) 36 (0.8%) <0.001 
            Chronic respiratory illnesses 
51 (1.0%) 23 (0.5%) 17 (0.3%) 14 (0.3%) 
<0.001 
 
             Pneumonia 
63 (1.2%) 48 (1.0%) 41 (0.8%) 29 (0.6%) 
<0.001 
 
Incidence (hospitalisation or mortality)      
            All (ex-lung cancer) 
1274 (25.1%) 1002 (20.7%) 889 (18.3%) 749 (16.5%) 
<0.001 
 
            Lung cancer 190 (3.7%) 70 (1.4%) 54 (1.1%) 53 (1.2%) <0.001 
            Chronic respiratory illnesses 
517 (10.2%) 355 (7.3%) 311 (6.4%) 270 (5.9%) 
<0.001 
 
            Pneumonia 
489 (9.6%) 357 (7.4%) 302 (6.2%) 228 (5.0%) 
<0.001 
 
Data presented are mean (SD) for continuous and number (%) for categorical data.  Q1 represents the lowest and the Q4 represents the highest quartiles 442 
groups of plasma vitamin C concentrations.  443 
  444 
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Table 2: Hazard ratios and corresponding 95% confidence intervals for incident any respiratory illness (except lung cancers), lung cancer, chronic respiratory 445 
illnesses and pneumonia by quartiles of plasma vitamin C concentration 446 
 Model 1  
(n=19,336):  
 
Model 2 
(n=18,890): 
 
Model 3 
(n=18,168): 
 
Model 4 
(n=17,744)  
Model 5 
(n=18,168)  
Model 6 
(n=17,744): 
 
Model 7 
(n=16,569)  
Any respiratory 
Condition1 
(events =3914) 
       
   Q1  1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.81 (0.74,0.88) 0.84 (0.78,0.92) 0.93 (0.85,1.01) 0.94 (0.86,1.03) 0.93 (0.85,1.01) 0.95 (0.87,1.04) 0.95 (0.86,1.04) 
   Q3 0.73 (0.67,0.79) 0.77 (0.71,0.85) 0.87 (0.79,0.95) 0.88 (0.81,0.97) 0.87 (0.80,0.96) 0.89 (0.81,0.98) 0.89 (0.81,0.98) 
   Q4  0.67 (0.61,0.73) 0.73 (0.66,0.80) 0.82 (0.74,0.90) 0.84 (0.76,0.93) 0.83 (0.75,0.91) 0.85 (0.77,0.95) 0.86 (0.77,0.95) 
Lung cancer2 
(events=367) 
       
   Q1  1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.40 (0.31,0.53) 0.42 (0.32,0.56) 0.58 (0.44,0.77) 0.59 (0.44,0.79) 0.58 (0.44,0.77) 0.59 (0.44,0.79) 0.61 (0.45,0.82) 
   Q3 0.34 (0.25,0.46) 0.38 (0.28,0.51) 0.51 (0.37,0.70) 0.53 (0.38,0.74) 0.51 (0.37,0.70) 0.53 (0.38,0.74) 0.55 (0.40,0.77) 
   Q4  0.38 (0.28,0.52) 0.43 (0.31,0.59) 0.55 (0.40,0.78) 0.58 (0.41,0.81) 0.55 (0.39,0.78) 0.57 (0.41,0.81) 0.53 (0.36,0.79) 
Chronic Respiratory 
illnesses 
(events =1,453) 
       
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.68 (0.60,0.78) 0.75 (0.65,0.86) 0.88 (0.76,1.01) 0.90 (0.78,1.04) 0.88 (0.76,1.01) 0.90 (0.78,1.04) 0.90 (0.77,1.04) 
   Q3 0.58 (0.51,0.67) 0.67 (0.58,0.78) 0.82 (0.71,0.96) 0.85 (0.73,0.99) 0.83 (0.71,0.96) 0.85 (0.73,0.99) 0.85 (0.73,1.00) 
   Q4 0.54 (0.46,0.63) 0.64 (0.55,0.75) 0.78 (0.66,0.92) 0.81 (0.69,0.96) 0.78 (0.67,0.92) 0.81 (0.69,0.96) 0.80 (0.67,0.95) 
Pneumonia 
(events =1,376) 
       
  Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Q2 0.77 (0.67,0.88) 0.81 (0.70,0.93) 0.86 (0.74,0.99) 0.87 (0.75,1.01) 0.86 (0.74,0.99) 0.88 (0.76,1.02) 0.88 (0.75,1.02) 
   Q3 0.68 (0.59,0.79) 0.71 (0.61,0.82) 0.78 (0.67,0.91) 0.79 (0.68,0.93) 0.79 (0.68,0.92) 0.81 (0.69,0.94) 0.81 (0.69,0.95) 
   Q4 0.55 (0.47,0.65) 0.60 (0.51,0.71) 0.66 (0.56,0.79) 0.68 (0.57,0.81) 0.68 (0.57,0.81) 0.70 (0.59,0.83) 0.70 (0.58,0.85) 
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1includes J45-J46, J00-J99, J40-J47, J12-J18, B012, B052, B953, B960, B961, J100, J110, J851; 2includes C33-C34. Q1 represents the lowest and the Q4 447 
represents the highest quartiles groups of plasma vitamin C concentrations.  448 
Model 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking, 449 
alcohol consumption, physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational social class and Townsend index of 450 
deprivation; 5) as in model 3 with additional adjustment for prevalent diabetes, MI and stroke; 6) (fully adjusted model) as in model 4 with additional 451 
adjustment for history of diabetes, myocardial infarction and stroke; and finally model 7 |(sensitivity model) was constructed as in model 6 after excluding 452 
participants who were taking vitamin C containing supplements.  453 
  454 
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Table 3: Hazard ratios and corresponding 95%CI for all respiratory deaths, lung cancer deaths chronic respiratory cause as cause of death and pneumonia 455 
deaths by quartiles of plasma vitamin C concentration 456 
 Model 1  
(n=19,336):  
 
Model 2 
(n=18,890): 
 
Model 3 (n=18,168): 
 
Model 4 
(n=17,744)  
Model 5 
(n=18,168)  
Model 6 
(n=17,744): 
 
Model 7  
(n=16,569)  
Any respiratory 
Condition1 
(events =407) 
       
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.77 (0.6,0.99) 0.78 (0.60,1.01) 0.89 (0.68,1.17) 0.93 (0.71,1.23) 0.89 (0.68,1.17) 0.93 (0.71,1.23) 0.95 (0.72,1.26) 
   Q3 0.69 (0.53,0.91) 0.74 (0.56,0.98) 0.89 (0.66,1.18) 0.93 (0.69,1.24) 0.89 (0.67,1.18) 0.93 (0.70,1.25) 0.96 (0.71,1.29) 
   Q4 0.59 (0.44,0.79) 0.68 (0.50,0.91) 0.79 (0.58,1.08) 0.81 (0.59,1.11) 0.80 (0.58,1.09) 0.81 (0.59,1.12) 0.87 (0.62,1.22) 
Lung cancer2 
(events=280) 
       
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.44 (0.32,0.59) 0.46 (0.34,0.63) 0.63 (0.46,0.88) 0.64 (0.46,0.89) 0.63 (0.46,0.87) 0.64 (0.46,0.89) 0.65 (0.46,0.91) 
   Q3 0.39 (0.28,0.55) 0.44 (0.31,0.61) 0.58 (0.40,0.83) 0.60 (0.41,0.86) 0.58 (0.41,0.83) 0.60 (0.41,0.86) 0.61 (0.42,0.89) 
   Q4 0.37 (0.25,0.53) 0.40 (0.28,0.59) 0.52 (0.35,0.78) 0.54 (0.35,0.81) 0.52 (0.35,0.78) 0.54 (0.35,0.81) 0.48 (0.30,0.77) 
Chronic 
Respiratory 
illnesses 
(events =105) 
       
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.50 (0.30,0.81) 0.56 (0.34,0.93) 0.87 (0.52,1.47) 0.96 (0.56,1.64) 0.87 (0.51,1.46) 0.95 (0.56,1.63) 0.93 (0.54,1.6) 
   Q3 0.40 (0.23,0.70) 0.47 (0.27,0.84) 0.73 (0.40,1.35) 0.83 (0.45,1.54) 0.74 (0.40,1.35) 0.84 (0.45,1.56) 0.81 (0.43,1.53) 
   Q4 0.38 (0.20,0.69) 0.55 (0.30,1.02) 0.73 (0.38,1.40) 0.84 (0.43,1.64) 0.74 (0.38,1.41) 0.85 (0.44,1.66) 0.63 (0.29,1.41) 
Pneumonia 
(events =181) 
       
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.82 (0.56,1.19) 0.79 (0.53,1.16) 0.78 (0.52,1.18) 0.85 (0.56,1.28) 0.78 (0.52,1.18) 0.85 (0.56,1.29) 0.86 (0.56,1.32) 
   Q3 0.76 (0.51,1.14) 0.79 (0.53,1.18) 0.84 (0.55,1.29) 0.90 (0.59,1.38) 0.85 (0.55,1.29) 0.91 (0.60,1.40) 0.97 (0.63,1.50) 
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   Q4 0.54 (0.35,0.86) 0.59 (0.37,0.94) 0.64 (0.40,1.02) 0.61 (0.37,1.00) 0.64 (0.40,1.04) 0.61 (0.37,1.01) 0.66 (0.39,1.10) 
1includes J45-J46, J00-J99, J40-J47, J12-J18, B012, B052, B953, B960, B961, J100, J110, J851; 2includes C33-C34. Q1 represents the lowest and the Q4 457 
represents the highest quartiles groups of plasma vitamin C concentrations.  458 
Model 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking, 459 
alcohol consumption, physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational social class and Townsend index of 460 
deprivation; 5) as in model 3 with additional adjustment for prevalent diabetes, MI and stroke; 6) (fully adjusted model) as in model 4 with additional 461 
adjustment for history of diabetes, myocardial infarction and stroke; and finally model 7 (sensitivity model) was constructed as in model 6 after excluding 462 
participants who were taking vitamin C containing supplements.  463 
 464 
 465 
 466 
 467 
  468 
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Figure 1: Hazard ratios for study outcomes in people in the highest quartile group (Q4) compared to the lowest quartile group (Q1) 
stratified by important factors for model 6. 
Figure 1 (a): Incident respiratory illness  
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Figure 1 (b): Incident lung cancer  
 
 
  
Figure 1 (c): Incident chronic respiratory diseases  
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Figure 1 (d): Incident pneumonia  
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Supplementary Material: Measurement methods 
The participants were asked about their medical history with the question, “Has a doctor ever 
told you that you have any of the following?”, in reference to the following conditions: 
stroke, heart attack, diabetes, cancer and respiratory diseases (asthma/COPD). Smoking 
history was obtained by asking the following yes or no questions: “Have you ever smoked as 
much as one cigarette a day for as long as a year?” and “Do you smoke cigarettes now?”. 
Participants who took any supplements or supplements containing vitamin C were identified 
from the question, “Have you taken any vitamins, minerals, or other food supplements 
regularly during the past year (such as vitamin C, vitamin D, iron, calcium, fish oils, primrose 
oil, β-carotene)?”, which was followed by “name/brand and dose.”  
 
Height and weight were measured, and body mass index (BMI) was calculated as weight (kg) 
divided by height squared (m2). Blood pressure (BP) was measured with an Accutorr monitor 
(Datascope, Huntingdon, United Kingdom) after the participant had been seated for 5 min. 
We used the mean of 2 measurements for analysis. Respiratory function was assessed by 
spirometry [12]. Spirometry (for measurement of FEV1 and FVC) was performed twice to 
ensure there were two acceptable flow volume loops using a portable spirometer (Micro 
medical, Rochester, UK), the higher of the two measures from either of the forced 
exhalations was used for analyses. 
 
A 4-level physical activity index was derived from the validated EPIC short physical activity 
questionnaire designed to assess combined work and leisure activity. Participants were 
categorized into inactive, moderately inactive, moderately active, and active categories. The 
validity and repeatability of this scoring system was detailed elsewhere [13]. We combined 
these into inactive (inactive and moderately inactive) and active (moderately active and 
active) categories.  Social class was classified according to the Registrar General's 
occupation-based classification scheme [14]. Social class I consists of professionals, social 
class II includes managerial and technical occupations, social class III is subdivided into 
nonmanual skilled workers and manual skilled workers, social class IV consists of partly 
skilled workers, and social class V comprises unskilled manual workers [15]. Social class 
was also combined as nonmanual (I, II, and III nonmanual) and manual (III manual, IV, and 
V) social classes. In addition we also used the Townsend deprivation index (TDI) as a 
measure of material deprivation; it takes into account of unemployment, car and home 
ownership within a household [16].   
 
Educational status was recorded as no qualification, O- level, A-level, degree or higher 
qualification. Educational attainment was re-categorised as low educational attainment (no or 
O level) and high educational attainment (at least A level). Alcohol consumption was derived 
from a food-frequency questionnaire (FFQ) collected at baseline. For the “drinks” category, 
responses ranging from never to >6 times/d were given for 4 types of alcoholic drinks. An in-
house computer program, CAFE, was developed for data entry and analysis [17].   
  
Supplementary Table 1: Hazard ratios (95%CI) for mortality respiratory illness, lung cancer, chronic respiratory diseases and pneumonia stratified by 1 
important factors for model 6.  2 
 Age <65 Age 65 or 
more 
Male Female Not 
Current 
smoker 
current 
smoker 
Physically  
Inactive 
Physically  
Active 
FEV (low) FEV (high)3 
Any 
respiratory 
Condition1 
(events 
=407) 
          
N (events) 91 273 200 164 290 74 266 98 310 54 
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 1.03 
(0.61,1.73) 
0.89 
(0.64,1.23) 
0.96 
(0.67,1.37) 
0.92 
(0.59,1.44) 
0.93 
(0.69,1.27) 
0.95 
(0.51,1.77) 
0.87 
(0.63,1.21) 
1.16 
(0.67,2.00) 
0.96 
(0.71,1.29) 
0.97 
(0.45,2.07) 
   Q3 0.82 
(0.45,1.49) 
0.99 
(0.71,1.38) 
1.03 
(0.7,1.52) 
0.88 
(0.56,1.38) 
0.95 
(0.69,1.31) 
0.96 
(0.46,2.01) 
0.84 
(0.6,1.19) 
1.27 
(0.72,2.24) 
1 
(0.73,1.37) 
0.7 
(0.31,1.55) 
   Q4 0.53 
(0.25,1.12) 
0.91 
(0.64,1.30) 
0.76 
(0.46,1.26) 
0.86 
(0.55,1.34) 
0.83 
(0.58,1.18) 
0.82 
(0.35,1.89) 
0.81 
(0.56,1.17) 
0.85 
(0.44,1.64) 
0.81 
(0.57,1.16) 
0.79 
(0.38,1.68) 
Lung cancer2 
(events=280) 
          
N (events) 132 125 180 77 154 103 164 93 230 27 
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 0.74 
(0.48,1.15) 
0.53 
(0.32,0.88) 
0.58 
(0.4,0.86) 
0.91 
(0.47,1.76) 
0.54 
(0.35,0.82) 
0.85 
(0.5,1.43) 
0.65 
(0.43,0.98) 
0.6 
(0.35,1.05) 
0.59 
(0.42,0.84) 
1.14 
(0.42,3.11) 
   Q3 0.56 
(0.33,0.93) 
0.64 
(0.38,1.08) 
0.47 
(0.29,0.77) 
1.03 
(0.55,1.95) 
0.61 
(0.4,0.94) 
0.48 
(0.23,1.01) 
0.63 
(0.4,0.99) 
0.55 
(0.29,1.02) 
0.56 
(0.38,0.83) 
0.96 
(0.33,2.77) 
   Q4 0.49 
(0.27,0.89) 
0.57 
(0.32,1.01) 
0.38 
(0.2,0.71) 
0.92 
(0.49,1.75) 
0.47 
(0.28,0.78) 
0.69 
(0.35,1.39) 
0.53 
(0.31,0.89) 
0.54 
(0.28,1.06) 
0.55 
(0.36,0.85) 
0.52 
(0.15,1.82) 
Chronic 
Respiratory 
condition 
(events 
=105) 
          
N (events) 35 62 63 34 50 47 68 29 92 5 
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 1.24 
(0.55,2.81) 
0.76 
(0.38,1.53) 
1.15 
(0.60,2.20) 
0.58 
(0.22,1.53) 
0.78 
(0.38,1.62) 
1.14 
(0.54,2.42) 
0.79 
(0.41,1.52) 
1.69 
(0.65,4.41) - - 
   Q3 1.27 
(0.49,3.28) 
0.62 
(0.27,1.42) 
0.92 
(0.41,2.07) 
0.68 
(0.26,1.79) 
0.8 
(0.36,1.78) 
0.86 
(0.32,2.29) 
0.69 
(0.33,1.47) 
1.53 
(0.50,4.70) - - 
   Q4 0.36 
(0.08,1.71) 
1.14 
(0.54,2.41) 
1.17 
(0.50,2.74) 
0.59 
(0.21,1.65) 
0.92 
(0.40,2.12) 
0.79 
(0.26,2.38) 
0.7 
(0.32,1.55) 
1.39 
(0.42,4.61) - - 
Pneumonia 
(events=158)           
N (events) 30 128 81 77 141 17 121 37 131 31 
   Q1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Q2 1.28 
(0.53,3.06) 
0.77 
(0.48,1.24) 
0.91 
(0.53,1.58) 
0.76 
(0.39,1.45) 
0.88 
(0.57,1.36) 
0.56 
(0.12,2.66) 
0.72 
(0.45,1.17) 
1.47 
(0.60,3.64) 
0.81 
(0.52,1.28) 
0.96 
(0.36,2.52) 
   Q3 0.96 
(0.36,2.60) 
0.93 
(0.58,1.49) 
1.05 
(0.59,1.88) 
0.8 
(0.42,1.51) 
0.93 
(0.59,1.46) 
0.85 
(0.18,4.08) 
0.87 
(0.54,1.42) 
1.27 
(0.48,3.37) 
1.03 
(0.65,1.61) 
0.52 
(0.17,1.58) 
   Q4 0.16 
(0.02,1.29) 
0.71 
(0.42,1.20) 
0.5 
(0.21,1.21) 
0.64 
(0.33,1.21) 
0.58 
(0.34,0.98) 
1.54 
(0.38,6.20) 
0.62 
(0.36,1.09) 
0.67 
(0.22,2.03) 
0.6 
(0.34,1.05) 
0.63 
(0.24,1.67) 
1includes J45-J46, J00-J99, J40-J47, J12-J18, B012, B052, B953, B960, B961, J100, J110, J851; 2includes C33-C34. 3 
3High FEV is defined as the upper quartile and low as the remaining. Q1 represents the lowest and the Q4 represents the highest quintiles groups of plasma 4 
vitamin C concentrations. 5 
Note due to the number of variables included in the models, some stratified analyses were not reported because number of events are less than required 6 
minimum number of events or two low. 7 
 8 
 9 
 10 
 11 
  12 
Supplementary Table 2: Hazard ratios (95%CI) for incidence and mortality of respiratory illness, lung cancer, chronic respiratory diseases and pneumonia in 13 
non-smokers and never-smokers  14 
  Incidence     Mortality   
 Model 6 
(non-
smokers) 
Model 6 
(never-
smokers) 
Model 7 
(non-
smokers) 
Model 7 
(never-
smokers) 
 Model 6 
(non-
smokers) 
Model 6 
(never-
smokers) 
Model 7 
(non-
smokers) 
Model 7  
(never-
smokers) 
Any 
respiratory 
Condition 
         
  Q1 1.00 1.00 1.00 1.00  1.00 1.00 1.00 1.00 
  Q2 0.98 
(0.89,1.08) 
1.04 
(0.89,1.22) 
0.98 
(0.89,1.08) 
1.04 
(0.88,1.22) 
 0.93 
(0.69,1.27) 
0.98 
(0.56,1.71) 
0.97 
(0.7,1.32) 
1.09 
(0.61,1.95) 
   Q3 0.91 
(0.82,1.01) 
0.92 
(0.78,1.08) 
0.91 
(0.82,1.01) 
0.92 
(0.78,1.08) 
 0.95 
(0.69,1.31) 
1.24 
(0.73,2.12) 
0.98 
(0.7,1.36) 
1.33 
(0.75,2.36) 
   Q4 0.89 
(0.79,0.99) 
0.82 
(0.69,0.97) 
0.89 
(0.79,1) 
0.81 
(0.67,0.96) 
 0.83 
(0.58,1.18) 
0.97 
(0.55,1.71) 
0.91 
(0.63,1.31) 
1.14 
(0.62,2.10) 
Lung cancer 
 
         
  Q1 1.00 1.00 1.00 1.00  1.00 1.001 1.00 1.001 
  Q2 0.49 
(0.34,0.72) 
0.58 
(0.18,1.83) 
0.51 
(0.35,0.75) 
0.60 
(0.19,1.9) 
 0.54 
(0.35,0.82) 
1.03 
(0.27,3.88) 
0.56 
(0.37,0.86) 
1.09 
(0.29,4.11) 
   Q3 0.53 
(0.36,0.79) 
0.93 
(0.34,2.54) 
0.55 
(0.37,0.83) 
0.75 
(0.26,2.18) 
 0.61 
(0.4,0.94) 
1.31 
(0.37,4.59) 
0.64 
(0.41,0.99) 
0.99 
(0.26,3.83) 
   Q4 0.58 
(0.38,0.88) 
1.11 
(0.41,3.01) 
0.60 
(0.39,0.94) 
0.91 
(0.31,2.66) 
 0.47 
(0.28,0.78) 
0.86 
(0.22,3.39) 
0.47 
(0.27,0.83) 
0.39 
(0.07,2.20) 
Chronic 
Respiratory 
illnesses 
         
   Q1 1.00 1.00 1.00 1.00  1.00 1.002 1.00 1.002 
   Q2 0.94 
(0.79,1.12) 
0.99 
(0.74,1.34) 
0.92 
(0.78,1.10) 
0.96 
(0.71,1.30) 
 0.76 
(0.37,1.59) 
0.95 
(0.05,16.89) 
0.80 
(0.38,1.68) 
1.08 
(0.06,18.77) 
   Q3 0.91 
(0.76,1.09) 
1.01 
(0.75,1.37) 
0.91 
(0.76,1.09) 
1.02 
(0.76,1.38) 
 0.82 
(0.37,1.81) 
1.45 
(0.09,24.45) 
0.79 
(0.35,1.80) 
1.73 
(0.10,29.65) 
   Q4 0.90 
(0.74,1.09) 
0.95 
(0.70,1.29) 
0.88 
(0.72,1.07) 
0.88 
(0.64,1.21) 
 0.94 
(0.41,2.18) 
4.41 
(0.45,43.20) 
0.65 
(0.23,1.83) 
2.14 
(0.16,28.18) 
Pneumonia          
   Q1 1.00 1.00 1.00 1.00  1.00 1.002 1.00 1.002 
   Q2 0.85 
(0.72,1.00) 
0.84 
(0.65,1.09) 
0.84 
(0.71,0.99) 
0.83 
(0.64,1.08) 
 0.88 
(0.57,1.36) 
0.71 
(0.33,1.52) 
0.87 
(0.56,1.36) 0.7 (0.32,1.53) 
   Q3 0.76 
(0.64,0.90) 
0.75 
(0.58,0.98) 
0.75 
(0.63,0.89) 
0.77 
(0.59,1.01) 
 0.93 
(0.59,1.46) 
1.26 
(0.64,2.47) 
0.98 
(0.62,1.54) 
1.32 
(0.65,2.66) 
   Q4 0.67 
(0.55,0.81) 
0.59 
(0.44,0.78) 
0.68 
(0.55,0.82) 
0.59 
(0.43,0.80) 
 0.58 
(0.34,0.98) 
0.56 
(0.25,1.28) 
0.63 
(0.36,1.09) 
0.62 
(0.26,1.47) 
1Excluded DM and CVA as could not be estimated from model due to lack of events.  15 
2Excludes adjustment for BMI, activity, Deprivation, DM, MI and CVA due to lack of events. 16 
Q1 represents the lowest and the Q4 represents the highest quintiles groups of plasma vitamin C concentrations. 17 
 18 
 19 
